Iodine Povacrylex

Investigated by: McMaster University · Patient-Centered Outcomes Research Institute · Universidad de El Salvador · University of Maryland, Baltimore

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	US (FDA)	DURAPREP	—	2006-09-29	fda.gov ↗

today

US approved 2006

200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 4	NCT03859908	Apr 2019 → Jan 2021	—	Universidad de El Salvador	Terminated	No outcome recorded
Phase 4	NCT03523962	Aug 2018 → Mar 2023	—	University of Maryland, Baltimore	Completed	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
—	NCT01233050 Comparator	Dec 2010 → Feb 2015	—	University of Pennsylvania	Completed	No outcome recorded

Every value below carries the sentence it was read from. 4 sources stand behind the page.

Field	Value	Cited text
Known as	iodine povacrylex	“The iodine-based treatment intervention is an antiseptic solution comprised of iodine povacrylex (0.7% free iodine) in 74% isopropyl alcohol.” NCT03523962 ↗ 2 NCT03859908 ↗ NCT01233050 ↗
Known as	Iodine povacrylex component of duraprep	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201721 ↗
Modality	Other / unclassified	“The iodine-based treatment intervention is an antiseptic solution comprised of iodine povacrylex (0.7% free iodine) in 74% isopropyl alcohol.” NCT03523962 ↗
Route	Topical	“pre-operative skin preparation with an antiseptic solution” NCT03523962 ↗